毛细胞白血病2022:诊断、风险分层和治疗更新
该综述更新了毛细胞白血病(HCL)及HCL样疾病的诊断、风险分层和治疗。诊断基于毛细胞形态学、HCL免疫学评分3或4分(CD11C、CD103、CD123、CD25表达)、骨髓活检评估浸润程度及BRAFV600E突变。风险分层依据脾大、白细胞增多、外周血毛细胞数量及免疫球蛋白重链可变区基因突变状态。治疗仅针对有症状患者,一线采用嘌呤类似物(PNA)化疗或化学免疫治疗(PNA联合利妥昔单抗),复发/难治疾病可用BRAF抑制剂联合利妥昔单抗、MEK抑制剂、CD22靶向免疫偶联物或BTK抑制剂。
要点
- 诊断需结合形态学、免疫学评分(CD11C、CD103、CD123、CD25,3或4分)、骨髓活检和BRAFV600E突变。
- 风险分层关注脾大、白细胞增多、外周血毛细胞数量及IGHV突变状态,VH4-34阳性提示预后不良。
- 仅症状性HCL需治疗,一线可选嘌呤类似物±利妥昔单抗,复发/难治可用BRAFi、MEKi、CD22免疫偶联物或BTKi。
核心结论
- HCL及HCL样疾病是异质性成熟B细胞淋巴瘤,诊断需综合形态学、免疫表型、骨髓活检和BRAFV600E突变。
- 治疗仅适用于有症状患者,一线风险适应嘌呤类似物化疗或化学免疫治疗,复发/难治有多种靶向药物可选。
研究设计与样本
- 综述,纳入HCL和HCL样疾病(HCL-V、SDRPL),更新诊断、风险分层和治疗策略。
主要发现
- HCL免疫学评分基于CD11C、CD103、CD123和CD25表达,3或4分支持诊断。
- VH4-34阳性HCL病例与不良预后相关。
- BRAF抑制剂联合利妥昔单抗或MEK抑制剂、CD22免疫偶联物、BTK抑制剂用于复发/难治HCL。
关键数值与推荐
- HCL免疫学评分3或4分(基于CD11C、CD103、CD123、CD25表达)支持诊断。
- 风险分层因素包括脾大、白细胞增多、外周血毛细胞数量高和IGHV突变状态。
临床怎么用
- 仅对症状性HCL患者启动治疗。
- 一线可选嘌呤类似物化疗或嘌呤类似物联合利妥昔单抗的化学免疫治疗。
- 复发/难治可选用BRAF抑制剂联合利妥昔单抗、MEK抑制剂、CD22免疫偶联物或BTK抑制剂。
局限性
- 不同治疗的最佳顺序尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Hairy cell leukemia (HCL) and HCL-like disorders, including HCL variant (HCL-V) and splenic diffuse red pulp lymphoma (SDRPL), are a very heterogeneous group of mature lymphoid B-cell disorders characterized by the identification of hairy cells, a specific genetic profile, a different clinical course, and the need for appropriate treatment. DIAGNOSIS: Diagnosis of HCL is based on morphological evidence of hairy cells, an HCL immunologic score of 3 or 4 based on the CD11C, CD103, CD123, and CD25 expression, the trephine biopsy which makes it possible to specify the degree of tumoral medullary infiltration and the presence of BRAFV600E somatic mutation. RISK STRATIFICATION: Progression of patients with HCL is based on a large splenomegaly, leukocytosis, a high number of hairy cells in the peripheral blood, and the immunoglobulin heavy chain variable region gene mutational status. VH4-34-positive HCL cases are associated with a poor prognosis. TREATMENT: Patients should be treated only if HCL is symptomatic. Chemotherapy with risk adapted therapy purine analogs (PNAs) are indicated in first-line HCL patients. The use of chemo-immunotherapy combining PNAs and rituximab (R) represents an increasingly used therapeutic approach. Management of relapsed/refractory disease is based on the use of BRAF inhibitors (BRAFi) plus rituximab or MEK inhibitors (MEKi), recombinant immunoconjugates targeting CD22 or Bruton Tyrosine Kinase inhibitors (BTKi). However, the optimal sequence of the different treatments remains to be determined. The Bcl2-inhibitors (Bcl-2i) can play a major role in the future.
引用
- Troussard X, Maître E, Cornet E, et al. Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment. Am J Hematol. 2021. PMID: 34710243. doi:10.1002/ajh.26390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。